Moreover, Ziesche ́ et al., [37] suggested that IL-22 production can be suppressed by the glucocorticoid dexamethasone (DEX) in the context of acute bacterial infections of SLE patients, while McKinley et al. [38] showed that IL-22 production was not responsive to DEX treatment at different doses. The gene discussed is IL22; the disease is systemic lupus erythematosus.